Arrowhead Pharmaceuticals, Inc.

The National Triglyceride Alliance plans to work with the American Society for Preventive Cardiology and other organizations with shared objectives to “provide evidence-based education, expert-driven resources and clinical guidance to healthcare providers.” Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. While preparing to go head to head in a rare disease market, the companies have signed up to be the top two sponsors of the newly launched National Triglyceride Alliance (NTA). The biotechs are both targeting conditions characterized by elevated triglyceride levels in the blood. Ionis won FDA approval for its antisense oligonucleotide Tryngolza late last year, and the FDA is reviewing Arrowhead’s application for approval of RNAi therapy plozasiran in the same indication. Both companies are also working to bring their molecules to market in another indication in which elevated triglycerides drive disease.While Ionis and Arrowhead are in direct competition, that rivalry gives the companies shared interest. Enter the NTA. The working group will “offer educational programs, clinical resources and ongoing initiatives aimed at improving understanding and treatment strategies for high triglycerides,” according to Friday’s launch announcement.Ionis is a founding sponsor of the NTA, Arrowhead is a national sponsor and Amarin, which sells Vascepa for use in certain adults with elevated triglycerides, has come on board as a local sponsor. The NTA lists the founder, national and local sponsorship levels at $250,000, $50,000 and $15,000, respectively. The NTA plans to work with the American Society for Preventive Cardiology and other organizations with shared objectives to “provide evidence-based education, expert-driven resources and clinical guidance to healthcare providers.” Through such initiatives, the NTA is aiming to give healthcare professionals the education and tools to effectively manage patients with high triglyceride levels. Ionis and Arrowhead are also working independently to lay the foundations for sales growth. With FDA approval in the bag, Ionis recently kicked off Tryngolza campaigns aimed at patients and healthcare professionals. Arrowhead, meanwhile, is yet to win approval but began priming the market last year with “We’ll Get There Soon,” a push to spread the word about the importance of treating patients with triglycerides above 500 mg/dL.

Supported by Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Amarin Corp, and Alliance Partners with Leading Medical Associations BOULDER, Colo., March 28, 2025 /PRNewswire/ -- The National Triglyceride Alliance (NTA) is proud to announce its official launch, marking a pivotal step in advancing education and awareness about the critical role of triglycerides in metabolic health. With the support of Founding Sponsor, Ionis, National Sponsor, Arrowhead Pharmaceuticals, and Local Sponsor, Amarin Corp, the NTA aims to transform clinical practice through education and advocacy, empowering healthcare professionals to prioritize proactive treatment of high triglycerides – saving lives, reducing risks and revolutionizing patient care. Our vision is to create a healthcare landscape where the treatment of high triglycerides becomes a core tenet of patient care. The NTA is honored to collaborate with its Alliance Manager, the American Society for Preventive Cardiology (ASPC) and esteemed Member Partners, Preventive Cardiology Nurses Association (PCNA), the National Lipid Association (NLA), the American Association for Clinical Endocrinology (AACE), the FCS Foundation, and the Foundation of the NLA (FNLA). Together, these organizations will work to provide evidence-based education, expert-driven resources, and clinical guidance to healthcare providers striving to improve patient outcomes. Millions of Americans live with elevated triglycerides, which are a significant yet often underrecognized factor in the cause of pancreatitis and cardiovascular disease. Despite the clinical importance of managing triglyceride levels, many healthcare professionals lack the necessary education and tools to effectively manage elevated triglyceride levels. The National Triglyceride Alliance seeks to close this gap in care by fostering collaboration among industry leaders, researchers, and frontline clinicians. "Our mission is to bridge the knowledge divide and ensure that clinicians recognize the need to proactively manage high triglycerides and are empowered with the most up-to-date science and clinically relevant treatment approaches," said Seth Baum, MD, MASPC, FACC, FAHA, FNLA, and Chairperson of the NTA. "With the generous support of Ionis, Arrowhead Pharmaceuticals, and Amarin, as well as the partnership of the ASPC, PCNA, NLA, the FCS Foundation, and the Foundation for the NLA, we look forward to transforming the paradigm of metabolic care, with a focus on increasing awareness of triglyceride management and its role in preventive care." The NTA will offer educational programs, clinical resources, and ongoing initiatives aimed at improving understanding and treatment strategies for high triglycerides. Through a combination of research dissemination, professional development, and strategic partnerships, the NTA seeks to redefine best practices in triglyceride management. For more information about the National Triglyceride Alliance, its educational initiatives, and upcoming events, please visit and follow us on social media: @NatTgAlliance on X, Bluesky and Instagram and @national-triglyceride-alliance on LinkedIn. SOURCE Innovative Biopharma, LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Decades ago, Amber Salzman remembers feeling like there was nothing she could do to help her cousin-in-law with a progressive muscle disease called facioscapulohumeral muscular dystrophy, or FSHD. She was a pharmaceutical executive who had successfully gotten a transformative gene therapy developed for her son, who was diagnosed with a deadly neurological disease, but she didn’t have a solution for FSHD because the cause of the disease was not well understood. “I’m a drug developer. I’m not a basic research scientist,” said Salzman, who is now CEO of Epicrispr Biotechnologies. “I don’t know how to fix this.” Fast forward to Wednesday. Epicrispr, which was previously more commonly known as Epic Bio, raised a $68 million Series B to study an epigenetic editing treatment in people with FSHD, a form of muscular dystrophy. The biotech received clearance from New Zealand authorities to begin a clinical trial of its experimental epigenetic editing treatment in adults with FSHD, and it plans to dose its first patient later this year. Over the last two decades, two key innovations led to this experimental therapy. First, researchers figured out the cause of FSHD — abnormal activation of a gene called DUX4 generates molecules that are toxic to the muscles. Second, as the name of the company suggests, CRISPR-based editing tools have enabled scientists to go after genetic diseases in new ways. Epicrispr was founded by Stanley Qi, an alum of Jennifer Doudna’s lab who now runs a lab at Stanford Medicine. Known as EPI-321, Epicrispr’s experimental one-time treatment is meant to silence DUX4 expression. It will be packaged and delivered via viral envelopes called AAVs. The therapy doesn’t cut DNA but rather methylates it — by adding a chemical group to silence gene expression. “What’s really exciting is we are actually going after the root cause,” Salzman said. The Series B was led by Ally Bridge Group and also included SOLVE FSHD, a venture fund started by Lululemon founder Chip Wilson, who was diagnosed with the disease. FSHD is a progressive muscle disease that primarily affects the muscles in the shoulders, arms and face. Investor interest in neuromuscular disease remains alive despite the broader downturn in the gene therapy and gene editing field. In November, Novartis bought muscular dystrophy gene therapy developer Kate Therapeutics for $1.1 billion. The same month, Sarepta made a $500 million upfront deal with Arrowhead Pharmaceuticals to work on a series of experimental rare disease treatments, including one for FSHD.